Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nitronazine by Guangzhou Magpie Pharmaceutical for Acute Ischemic Stroke: Likelihood of Approval
Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Acute Ischemic Stroke. According to...
Nitronazine by Guangzhou Magpie Pharmaceutical for Type 2 Diabetes: Likelihood of Approval
Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Type 2 Diabetes. According to...
Nitronazine by Guangzhou Magpie Pharmaceutical for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Amyotrophic Lateral Sclerosis. According to...